

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar


<b>Adopted By PBSL</b>	
<b>Start of public Consultation</b>	
<b>End of public Consultation</b>	
<b>Agreed by QMS committee</b>	
<b>Approved by Board</b>	

**Pharmacy Board of Sierra Leone,  
PMB 322  
Central Medical Stores Compound  
New England Ville  
Freetown**

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

## Table of Contents

Acknowledgements .....	3
Executive Summary .....	3
1.0 INTRODUCTION .....	3
2.0 OBJECTIVE.....	3
3.0 SCOPE .....	4
4.0 REQUIREMENTS.....	4
4.1 GENERAL REQUIREMENTS .....	4
4.2 SPECIFIC REQUIREMENTS FOR DRUGS.....	6
4.3 PRESCRIPTION AND PHARMACY DRUGS: .....	7
4.4 OVER THE COUNTER MEDICINES (OTC'S) .....	10
5.0 GLOSSARY .....	11
6.0 REFERENCES .....	13
7.0 ANNEXES .....	13

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

## Acknowledgements

## Executive Summary

### 1.0 INTRODUCTION



In pursuance of Sections 35 of the Pharmacy and Drugs Act 2001 these guidelines are hereby made to provide guidance to applicants on the procedure for writing and registering an advertisement script in Sierra Leone.

Applicants are encouraged to familiarize themselves with this document and the above law before initiating the registration process.

### 2.0 OBJECTIVE

This guideline has been designed to assist in the following;

- Provide guidance on the contents of advertisement and the type of products that are eligible to be advertised on the electronic and print media.
- To help facilitate advertisement approval after thorough vetting by various technical staff of the Pharmacy Board.

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

- To ensure adequate compliance with the provisions of this guidelines in order to effectively control product advertisement.



### **3.0 SCOPE**

This Guideline is developed in pursuance of Section 35 of the Pharmacy and Drugs Act 2001. This Guideline applies only to Over the Counter medical products that have been granted Marketing Authorization Certificates by the Pharmacy Board. It provides recommendations for applicants preparing applications for advertisement of OTC products.

### **4.0 REQUIREMENTS**

#### **4.1 GENERAL REQUIREMENTS**

1. No person shall advertise any product unless the product is registered with the Board.
2. No person shall advertise any product unless such advertisement has been approved by the Board.
3. No advertisement shall contain more than one product per script per media per language, unless the products are related. Any additional product or language on a script shall attract an additional approval fee.

	<p align="center"><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>

4. No person or media house shall carry any advertisement of a product in the print or electronic media or by any means unless there is evidence of prior approval of the advertisement granted by the Board.

4. An advertisement shall not contain material, which refers to recommendations by scientists or health professionals or which refers to recommendations by celebrities or well-known organizations, which because of their status could encourage consumption of products.



6. No advertisement shall be targeted at pregnant or lactating women and persons with disease conditions specified in second Schedule (section 35) of the Pharmacy and Drugs Act 2001.

7. An advertisement shall be accurate, complete, clear and designed to promote credibility and trusted by the general public and health practitioners. Statements or illustrations must not mislead directly or by implication.

8. No advertisement shall bring the respective industry into disrepute, undermine confidence in advertising or prejudice public confidence in the product.

9. No advertisement shall unfairly disparage any product of a competitor, either directly or by implication.

10. No advertisement shall imitate the general layout, text slogans or visual presentation or devices of other advertisements from other companies in a way likely to mislead, deceive or confuse the consumer.

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

11. No advertisement shall be framed in such a manner as to exploit the superstitious belief and/or induce fear in the consumer to purchase the product. No advertisement shall contain words such as magic, miracle or mystical; exotic descriptions, such as 'super potency' or such other words as to induce the daily and continuous use of the product.



12. No OTC drug advertisement shall:

- a. Imply that the consumer is suffering, or without treatment may suffer or suffer more severely from any illness, ailment or disease.
- b. Over-dramatize any symptoms or signs.
- c. Denigrate or attack unfairly any competitive products, goods and services.

13. Advertisements for a product shall present information that is reasonably balanced between side effects and contra-indications and efficacy and safety.

## **4.2 SPECIFIC REQUIREMENTS FOR DRUGS**


1. Drug advertising shall reflect an overall attitude of caution in relation to drug usage, with emphasis on rational use of medicines. It shall provide sufficient and balanced information to permit assessment of risk against the benefits.

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

2. No advertisement for drugs shall contain any price, competition or similar scheme.
3. No drug advertisement shall contain offers of gifts or refund of money to dissatisfied consumers.
4. No drug advertisement shall state or imply in absolute terms or by quotations taken out of context, that any pharmaceutical product is 'safe', 'non-toxic' or 'has guaranteed efficacy'.
4. An advertisement which contravenes the ethical standards of the health and other professions is prohibited.
6. No drug advertisement shall make statements claiming or implying superlative functions such as being the "drug of choice", 'the most frequently prescribed', 'the only drug for the purpose or that the drug has no side effects, unless such claims can be adequately and scientifically substantiated.
7. Advertisements of all drugs that may be used by pregnant women and lactating mothers shall state any known effects of the drug on the pregnant woman, fetus and infant.
8. The indications for use of any therapeutic agent must conform to the approved product monograph and label.

#### **4.3 PRESCRIPTION AND PHARMACY DRUGS:**



	<p align="center"><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>

1. No person shall advertise any prescription drug in the lay press or non-medical press.

2. Prescription drugs shall be advertised only for indications for which the drug has been registered by the Authority.

3. No person shall advertise any prescription drug in a health professional journal unless the drug is properly labeled, and the advertisement contains the following information;

(1) Names of drug product - International non-proprietary and brand name

(2) A quantitative listing of all the ingredients

(3) An accurate statement of the dosage and strength

(4) Daily dose

(5) Frequency of administration

(6) Preparation before use (shaking, dilution, refrigeration)


(7) Quantity of contents in metric units where applicable

(8) Route or method of administration

(9) Adequate warning (cautions, side effects, interactions, treatment of overdose, effects on pregnancy and lactation, when necessary for the protection of the user as provided in drug labeling regulations.

(10) Name and address of manufacturer or packaging company. If an imported drug, the name and address of the local packing company or



	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

distributor must appear on the label in such a manner as to identify the relationship between the packing company or distributor with such drug.



4. All Prescribing information must be legibly presented.

4. All data illustrations presented in advertisements including charts, graphs and tables extracted from the literature or other sources or reproduced by artwork, must be accurate, complete and clear with the source specifically identified. Data illustrations which are misleading or ambiguous or which distort the original intended meaning or interpretation either directly or by implication will be considered a violation of these regulations.

6. Claims and quotations from the scientific literature concerning efficacy, safety, adverse reactions, use in children below the age of eighteen, use in pregnancy and lactation within the constraints of the product monograph, shall mention the scientific source(s) of information. Copies of all references cited should be provided to the Board for verification.

7. Claims based on, or quotations that have been selected from a scientific article or series of articles and emphasize only positive features while ignoring negative findings, will not be accepted. Claims and quotations must be readily verifiable by the Board.


8. Selected quotations should not refer to another brand of the same pharmaceutical entity or to a different formulation of the same active

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

ingredients unless data of accepted methodology are available to warrant cross reference between products

#### **4.4 OVER THE COUNTER MEDICINES (OTC'S)**



1. OTC medicines including allopathic, food supplements, herbal and homeopathic, shall not be advertised for diseases specified in the second Schedule of the Pharmacy and Drugs Act 2001, Section 34.
2. An advertisement shall advise the consumer on any age restrictions and special precautions and the need to seek medical attention should the symptoms persist after 72 hours.
3. An advertisement shall indicate that its contents has been vetted and approved by the Pharmacy Board of Sierra Leone.

	<p align="center"><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>

## 5.0 GLOSSARY

In these guidelines, unless the context otherwise states: -

- a) 'Product' means drugs (including orthodox, herbal and homoeopathic), cosmetics, medical devices and household chemical substances.
- b) 'Related Products' means products that are complementary products or products with different strengths, pack-sizes or are variants of the same products (different flavors).
- c) 'Drug product' means a substance or mixture of substances manufactured, sold, or presented for in-vivo use in the diagnosis, treatment, mitigation or prevention of a disease disorder, abnormal physical state, or the symptoms thereof; or in restoring, correcting or modifying organic function(s) in man, but excluding mechanical devices and cosmetics.
- d) 'Rational Drug Therapy' means appropriate therapy, recommended or prescribed which legally may be expected to remedy or ameliorate a disordered state of physical or mental health? Drugs may be logically employed for diagnostic and prophylactic purposes to prevent or lower the incidence of illness.
- e) 'Full Disclosure' as used in this context means adequate information for the

	<p align="center"><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>



prescriber concerning the accepted indications and appropriate use of the product, including warning precautions, contraindications, adverse reactions, dosage forms and dosage regimens.

f) 'Therapeutic classification of a pharmaceutical product' means either the accepted pharmacological classification (anxiolytic, diuretic, analgesic, antibiotic) or the identity of the purpose or purposes for which the pharmaceutical product (as defined) is intended (migraine, hypertension) or both.

g) 'Advertising' means the publicity of goods and description of all products; this includes any form of notices in circulars, handouts, label wrappers, catalogue and price lists, newspaper, magazines and many other documents made orally or otherwise or by means of projected light, sound recording, Radio, presenter mentions, television, bill boards, mobile vans and writings.

h) 'Over-the-counter drugs (OTC)' means drugs that are generally regarded as safe for the consumer for use by following the required label directions and warnings. They may be purchased without a prescription.

i) 'Prescription Drugs' means a drug which can only be made available to consumer through a written order signed by a duly qualified and registered medical practitioner, dentist or veterinary surgeon and disposed by a fully registered and licensed pharmacist.

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

Such drugs shall not be made available or sold directly to the general public without the said written order.

They are identifiable under the Scientific or Chemical names of their active ingredients as well as by the generic or established names of the active ingredients.

j) 'Label' means a display of written printed or graphic matter upon the immediate drug container.

k) 'Package Labeling' includes the label on the immediate containers plus all other printed matter, such as outer wrapper, carton or leaflet associated with the package.

l) 'Appropriate authority' means the Registrar of the Board.

m) 'Claims' means any representation which states, suggests or implies that a drug has particular qualities relating to its origin, properties, nature, processing, composition or any other quality.



n) 'Justification' in respect of any claim shall be in the light of current scientific knowledge.

o) 'Board' means the Pharmacy Board of Sierra Leone



## 6.0 REFERENCES

Pharmacy and Drugs Act 2001

## 7.0 ANNEXES

	<p><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>

**NONE**

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

## **7.0 APPENDIX**

### **7.1 APPLICATION**


1. An application for the advertisement of a product shall be accompanied by:

- (a) A duly signed covering letter
- (b) Two (2) samples of the product in the final package and ready for the market
- (c) Proposed script or story sketch intended for the advertisement
- (d) Non-refundable application fee as specified in the Board's Fee Schedule.

2. The proposed script shall be approved before the final print, audio Cassette, video cassette, compact disc is made to be broadcast or telecast.

3. The final version of the advertisement in whatever form shall be submitted for vetting before publication.



	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

4. Advertisements considered unacceptable by the Board will be communicated to the advertiser with the unacceptable information or illustration clearly clarification on the ruling will be given in writing.

4. The duration of an approval for an advertisement will be one (1) year from the date of approval.



6. Any alterations in the format of the approved script, film or story sketch without express written permission of the Pharmacy Board of Sierra Leone shall render the approval null and void and shall attract a penalty.

7. Notwithstanding the above, the Board reserves the right to revoke approval as a result of new evidence concerning product or public safety or product efficacy or quality.

8. If approval of an advertisement is withdrawn during the one year period of approval, an appeal may be made to the Registrar in writing and accompanied by supporting information. Such an appeal shall be lodged with the Registrar within twenty one (21) days of notification and supporting materials provided within sixty days of notification.

9. In the event of any publication of an advertisement not approved by the Authority, the sponsor, advertising agent and the advertising media organization shall be jointly and severally liable.

## **7.1 APPENDIX 2.0**


	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

### **PHARMACY AND DRUGS ACT, 2001, SECOND SCHEDULE (Section 35)**

Diseases in respect of which advertisement for treatment, prevention or cure are prohibited. Sexually Transmitted Diseases, other forms of Genito-Urinary diseases. Acquired Immune Deficiency Syndrome (AIDS) or diseases connected with the human reproductive functions.

Any of the following:-

Alcoholism  
 Appendicitis  
 Amenorrhoea  
 Arterio-Sclerosis (Strokes)  
 Asthma  
 Bladder Stones  
 Blindness  
 Blood disorders  
 Cancer  
 Cataract  
 Cholera  
 Convulsion  
 Deafness

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

Diabetes

Diphtheria

Diseases of the reproductive organ

Fibroid

Erysipelas

Epilepsy or fits

Gallstones

Goitre

Heart Disease

Hepatitis

Hernia or Rupture

Hypertension

Infertility

Influenza

Jaundice

Kidney Stones

Kidney Failure



Leprosy

Leukemia



Locomotor ataxis

Measles

Mental Disorders

	<p align="center"><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>

Mumps  
 Nervousness  
 Nephritis or Bright's disease  
 Nutritional agents  
 Obesity  
 Onchocerciasis  
 Systemic Lupus Erythematosus  
 Palsy  
 Paralysis  
 Plague  
 Pleurisy  
 Pneumonia  
 Poliomyelitis  
 Prostate Diseases  
 Rabies  
 Rheumatic fever  
 Scarlet Fever  
 Schistosomiasis  
 Septicaemia  
 Sexual Impotence  
 Sexual transmitted disease  
 Sterility

	<b>Title: Guideline for advertisement of pharmaceutical/regulated products</b>	
<b>Rev No: 02</b>	<b>Doc No: PBSL/GL/036</b>	Version no. 03
<b>Issue date: 15 May 2024</b>	<b>Effective date: 17 May 2024</b>	Approved by: Registrar

Sleeping sickness

Smallpox

Snake bite

Tetanus or Lock-jaw

Trachoma

Tuberculosis

Tumours

Typhoid fever

Ulcers

Yaws

Yellow fever

***Prepared by***

***Reviewed by***

***Approved by***

Head of DERD

Head, Quality Assurance



Registrar

Dr Sheku S Mansaray

Dr Michael Lahai

Dr James P.

Komeh

	<p><b>Title: Guideline for advertisement of pharmaceutical/regulated products</b></p>	
<p><b>Rev No: 02</b></p>	<p><b>Doc No: PBSL/GL/036</b></p>	<p>Version no. 03</p>
<p><b>Issue date: 15 May 2024</b></p>	<p><b>Effective date: 17 May 2024</b></p>	<p>Approved by: Registrar</p>